Mergers & acquisitions
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
While public perception of the pharmaceutical industry is on an upswing among the general population due to rapid vaccine and therapeutic development during the COVID-19 pandemic, in the eyes of credit rating agencies, the industry is on a continued downward spiral.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
Charles River Laboratories will acquire Cognate BioServices in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.
The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX.
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.
PRESS RELEASES